Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Slate Medicines has raised $130.0M in total funding. The most recent round was Series A. The last funding was announced in February 2026.
Slate Medicines is headquartered in Raleigh, United States.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Slate Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Slate Medicines — Funding & Investors." VCBacked, February 24, 2026, https://www.vcbacked.co/company/slate-medicines. Accessed September 10, 2026.
VCBacked. (2026). Slate Medicines — Funding & Investors. Retrieved September 10, 2026, from https://www.vcbacked.co/company/slate-medicines
{{cite web |title=Slate Medicines — Funding & Investors |url=https://www.vcbacked.co/company/slate-medicines |website=VCBacked |access-date=September 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated